Information Provided By: 
Fly News Breaks for April 21, 2015
LGND, TGTX
Apr 21, 2015 | 09:16 EDT
After TG (TGTX) presented preclinical data at AACR for its two IRAK4 inhibitors licensed from Ligand (LGND), Roth Capital believes the data show that at least these two agents have promising prospects as single agent therapies and at least one of these agents also shows promise in combination with TG's own TGR-1202 and irbutinib. The firm thinks the data also highlights the opportunity to combine inhibition of various kinases to achieve increased anti-tumor effects. Roth reiterates a $33 price target, Focus Pick and Buy rating on the shares.
News For TGTX;LGND From the Last 2 Days
There are no results for your query TGTX;LGND
